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Chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative disorders (LPDs) show clear evidence of
familial aggregation, but the inherited basis is largely unknown. To identify a susceptibility gene for CLL, we conducted
a genomewide linkage analysis of 115 pedigrees, using a high-density single-nucleotide polymorphism (SNP) array
containing 11,560 markers. Multipoint linkage analyses were undertaken using both nonparametric (model-free)
and parametric (model-based) methods. Our results confirm that the presence of high linkage disequilibrium (LD)
between SNP markers can lead to inflated nonparametric linkage (NPL) and LOD scores. After the removal of
high-LD SNPs, we obtained a maximum NPL of 3.14 ( ) on chromosome 11p11. The same genomicPp .0008
position also yielded the highest multipoint heterogeneity LOD (HLOD) score under both dominant (HLOD 1.95)
and recessive (HLOD 2.78) models. In addition, four other chromosomal positions (5q22-23, 6p22, 10q25, and
14q32) displayed HLOD scores 11.15 (which corresponds to a nominal P value !.01). None of the regions coincided
with areas of common chromosomal abnormalities frequently observed for CLL. These findings strengthen the
argument for an inherited predisposition to CLL and related B-cell LPDs.
Introduction
Leukemia affects 1%–2% of the population of Western
countries (Ries et al. 2003). B-cell chronic lymphocytic
leukemia (CLL [MIM 151400]) is the most common form
of leukemia (∼30% of all cases) (Ries et al. 2003). Family
and epidemiological studies have now provided strong
support for the existence of inherited susceptibility to
CLL (reviewed by Sellick et al. [2004a]) and other B-
cell lymphoproliferative disorders (LPDs), such as non-
Hodgkin lymphoma (NHL [MIM 605027]) and Hodg-
kin lymphoma (HL [MIM 236000]). In the literature,
150 families have been described that show distinct clus-
tering of CLL, and many striking multiple-case families
provide very strong evidence of an increased familial risk
(reviewed by Houlston et al. [2003]). Although no for-
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mal modeling of the inheritance of CLL-LPD in fami-
lies has been undertaken, a number of large pedigrees
described in the literature are compatible with the exis-
tence of dominantly acting alleles with pleiotropic effects
(Schweitzer et al. 1973; Gunz et al. 1975). Case-control
and cohort studies that have systematically estimated the
familial risk of CLL and other LPDs (Cartwright et al.
1987; Linet et al. 1989; Pottern et al. 1991; Radovanovic
et al. 1994; Goldin et al. 2004) have shown that all
B-cell LPDs display site-specific elevated familial risks—
particularly for CLL, for which risks are increased seven-
fold in first-degree relatives of patients (Goldin et al.
2004). Furthermore, these studies have also demon-
strated that familial associations exist between the dif-
ferent types of B-cell LPDs, with risks of NHL and HL
showing twofold increases in relatives of patients with
CLL (Goldin et al. 2004).
In 1997, we formed an International CLL Linkage
Consortium (ICLLC) to collect biological samples and
data from families with CLL and other B-cell LPDs, to
identify predisposition genes for these diseases. Here, we
report the results of a genomewide linkage search of 115
families segregating CLL with or without additional B-
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cell LPD cases ascertained through the consortium. Since
increased genetic-marker density in whole-genome scans
has been shown to increase the linkage information con-
tent (IC) (Schaid et al. 2004), we conducted our genome-
wide scan using the recently introduced Affymetrix Map-
ping 10Kv1 array, which contains ∼11,000 SNP markers.
Methods
Ascertainment and Collection of Families
Through hematologists in the United Kingdom, Nor-
way, Israel, Italy, Ireland, Germany, Portugal, The Neth-
erlands, and Australia who participate in the ICLLC,
115 families with two or more affected individuals with
B-cell CLL, with or without the segregation of additional
B-cell LPD cases (B-cell NHL or HL), were ascertained.
The diagnoses of B-cell CLL and other B-cell LPDs in
affected family members were established, in all cases,
using accepted standard clinicopathological and immuno-
logical criteria that are in accordance with current World
Health Organization classification guidelines (Mu¨ller-
Hermelink et al. 2001). Samples were obtained with in-
formed consent and local ethical review board approval,
in accordance with the tenets of the Declaration of Hel-
sinki. DNA was salt extracted from patient samples by
use of a standard sucrose lysis method and was quanti-
fied using PicoGreen reagents (Invitrogen).
Genotyping
A genomewide linkage search of the 115 families was
undertaken using the GeneChip Mapping 10Kv1 Xba
Array containing 11,560 SNP markers (Affymetrix). SNP
genotypes were obtained by following the Affymetrix pro-
tocol for the GeneChip Mapping 10K Xba Array (Mat-
suzaki et al. 2004). In brief, 250 ng of genomic DNA
isolated from peripheral blood was digested per sample,
with the restriction endonuclease XbaI, for 2.5 h. Di-
gested DNA was mixed with Xba adapters and was li-
gated, using T4 DNA ligase, for 2.5 h. Ligated DNA
was added to four separate PCR reactions and was cy-
cled, pooled, and purified to remove unincorporated
ddNTPs. The purified PCR products were then frag-
mented and labeled with biotin-ddATP. Biotin-labeled
DNA fragments were hybridized to the arrays for 18 h
in an Affymetrix 640 hybridization oven. After hybridi-
zation, arrays were washed, stained, and scanned using
an Affymetrix Fluidics Station FS450 with images ob-
tained using an Affymetrix GeneChip 3000 scanner. Af-
fymetrix GCOS software (v1.2) was used to obtain raw
microarray feature intensities (RAS scores). RAS scores
were processed using Affymetrix GDAS (v3.0.2) soft-
ware to derive SNP genotypes.
Data Manipulation and Error Checking
Non-Mendelian error checking of genotypes and the
generation of linkage format files from raw Affymetrix
array files (with the suffix “.chp”) were performed using
the program ProgenyLab (Progeny). The map order and
distances between SNP markers were based on the Uni-
versity of California–Santa Cruz Human Genome brows-
er (May 2004 release). The program MERLIN was em-
ployed to search for additional unlikely genotypes that
are consistent with potential genotyping errors (Abecasis
et al. 2002).
Investigation of Linkage Disequilibrium
Currently available linkage software for multipoint an-
alyses assumes that all markers are in linkage equilib-
rium. However, for closely spaced SNP markers, this
assumption may not always be correct. To identify mark-
ers in high linkage disequilibrium (LD), we calculated
the pairwise LD measures and between consecutive2 ′r D
pairs of SNP markers. We simplified our approach by
ignoring relationships among family members and by
using the expectation-maximization algorithm to esti-
mate two-locus haplotype frequencies, from which 2r
and were computed. Although ignoring relationships′D
may result in a loss of efficiency, it should not signifi-
cantly bias estimates. A pair of SNPs was defined as
being in high LD if they had a pairwise LD measure of
. LD was then removed by considering each set2r 1 0.4
of markers in LD (defined as sets in which each consecu-
tive marker pair in the set had ) and retaining2r 1 0.4
one SNP from each set (the centrally positioned SNP).
The impact of LD was investigated by considering link-
age results calculated before and after the removal of
the high-LD SNPs.
Linkage Analysis
Multipoint linkage analysis was undertaken by imple-
mentation of the Perl script SNPLINK, which performs
fully automated nonparametric (mode-of-inheritance
free) and parametric analyses before and after LD re-
moval, by incorporation of the MERLIN (v0.10.1) (Abe-
casis et al. 2002) and ALLEGRO (v1.1) (Gudbjartsson
et al. 2000) programs, respectively (Webb et al. 2005).
Parametric linkage in the presence of heterogeneity was
assessed using heterogeneity LOD (HLOD) scores.HLOD
scores and the accompanying estimates of the proportion
of linked families (a) were calculated using the statistical
software package ALLEGRO. These analyses require the
specification of a disease-transmission model. We de-
rived LOD scores under both dominant and recessive
models of inheritance, with reduced penetrance and
three age categories dependent on age at diagnosis (!50,
50–70, or 170 years). In the absence of a genetic model
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Table 1
Characteristics of the 115 Pedigrees with CLL or CLL/B-Cell LPDs
No. of Affected
Individuals
per Pedigree
No. of
Pedigreesa
Total No.
Affectedb
Total No.
DNA Typedb
2 80 (11) 160 (11) 147 (10)
3 28 (3) 84 (5) 57 (3)
4 5 (2) 20 (3) 16 (2)
5 1 (0) 5 (0) 3 (0)
12 1 (1) 12 (1) 5 (1)
Total 115 (17) 281 (20) 228 (16)
NOTE.—All affected individuals had CLL, B-cell NHL, or HL.
a The number of pedigrees with individuals affected with non-CLL
LPDs is shown in parentheses.
b The number of individuals affected with non-CLL LPDs is shown
in parentheses.
and parameters from segregation analysis of familial data,
we chose values that were consistent with the population
age-specific risks of CLL and compatible with the ob-
served familial risks (Goldin et al. 2004). The lifetime
risk (defined at age 80 years) of being diagnosed with
CLL in the U.S. population, by use of the Surveillance
Epidemiology and End Results (SEER) data, is estimated
to be 0.37% (Ries et al. 2003). We assumed an allele
frequency of 0.0005 under the dominant model and 0.05
under the recessive model. To satisfy the constraints of
the lifetime risk and familial relative risks, for the domi-
nant model, penetrance was assumed to be 2% for in-
dividuals aged !50 years, 17% for individuals aged 50–
70 years, and 36% for those aged 170 years. For the
recessive model, the penetrances were assumed to be 2%,
14%, and 30% for the three liability classes. To allow
for phenocopies, the penetrances for the normal geno-
types under both models were set to 0.006%, 0.2%, and
0.3%.
All unaffected individuals were considered uninforma-
tive (i.e., of unknown phenotype) for the analysis. HLOD
scores follow a complex statistical distribution, which
can be approximated by the maximum of two indepen-
dently distributed variables. To obtain significance2x1
estimates for HLODs, these variables were first con-
verted to a , where , and sig-2 2x x p 2 log 10#HLODe
nificance values (P1) were then derived, using the dis-2x
tribution with 1 df. The nominal P value for the HLOD
score is then given by (Far-0.5# [1 (1 P )(1 P )]1 1
away 1993).
Multipoint nonparametric linkage (NPL) analyses were
performed using the SALL statistic (Whittemore and Hal-
pern 1994) generated by the program MERLIN. Results
are reported in terms of an NPL statistic and its asso-
ciated one-sided P value. Under the null hypothesis of
no linkage, the NPL statistic is distributed asymptoti-
cally as a standard normal random variable. We also
calculated empirical genomewide significance levels for
the NPL statistics after markers in high LD were re-
moved, using 10,000 gene-dropping simulations. In each
simulation, we used MERLIN to simulate genotype data,
using the original phenotypes, allele frequencies, marker
spacing, and missing-data patterns. Empirical limits for
genomewide significance were established at 3.59, with
the suggestive linkage threshold at 2.80. The genome-
wide significance thresholds represent the NPL score that
could be achieved with our data by chance under the
null hypothesis of no linkage, at a frequency of 1 in 20
simulations, whereas the genomewide suggestive thresh-
olds represent the values that could be obtained by
chance once in every genomewide scan. MERLIN was
also used to estimate IC for each chromosome provided
by the marker set, by use of the entropy information
described by Kruglyak et al. (1996).
Results
Description of Families Analyzed
Descriptions of the 115 families (98 with CLL; 17
with CLL/B-cell LPD) are summarized in table 1. In to-
tal, there were 261 individuals affected with CLL (Inter-
national Classification of Diseases, Ninth Edition [ICD-
9] of 204.1); 18 individuals affected with NHL (ICD-9
of 202), and two individuals affected with HL (ICD-9
of 201.5-9). The number of affected persons per family
had a range of 2–12, and the number of affected persons
per family with DNA available had a range of 2–4. There
were 25 families with affected persons in two or more
generations; one pedigree contained affected family
members in three generations, and one pedigree con-
tained affected individuals in four generations. All other
families contained affected family members in only one
generation.
In the families, the median age at diagnosis of CLL was
61 years, significantly less than the median value of 72
years for age at diagnosis observed in the general white
population (Ries et al. 2003). Minimum age at diagnosis
within a family is likely to be a superior indicator of the
potential for existence of a susceptibility gene, since it
is not influenced by older sporadic cases. In our families,
the minimum age at diagnosis within the families had a
range of 31–81 years, with a median value of 58 years.
Of the 115 pedigrees analyzed, 105 had successfully
completed analyses (genotypes available for2 affected
individuals informative for linkage). Ten pedigrees could
not be analyzed completely because of poor DNA qual-
ity, which gave genotyping call rates of !85%, or be-
cause of insufficient amounts of starting material from
a deceased individual. Of the 105 families used in the
linkage analyses, 89 were documented as segregating
CLL only, 15 as segregating both CLL and B-cell NHL,
and 1 as segregating both CLL and HL. Twenty-four of
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Figure 1 Distribution of pairwise and according to pairwise distance between SNP markers. The horizontal line shows the criterion′ 2D r
used to define high-LD SNPs: .2r 1 0.4
the families had affected individuals in two or more
generations.
Data Quality
A total of 228 Affymetrix Mapping 10Kv1 arrays were
processed, which resulted in the generation of 12.45 mil-
lion genotypes. We monitored a number of parameters
throughout the study, to determine data quality, and all
genotypes were housed within the pedigree-data-storage
program ProgenyLab. The average SNP call rate per ar-
ray was 92.2%. For DNA extracted from males, it was
possible to examine the 309 markers on the X chromo-
some for errors due to miscalls or PCR contamination.
No SNPs were heterozygous in male samples. Of the
SNPs, 106 were excluded because their chromosomal po-
sition was unknown (Affymetrix NetAffx 10K_XBA131
[January 2005 release]), and 210 SNPs were not poly-
morphic in our pedigree set, which left 11,244 poly-
morphic markers with known map locations. After error
checking with the programs ProgenyLab and MERLIN,
a total of 517 and 2,826 genotypes, respectively, were
deemed to be erroneous and were removed from further
analysis.
Linkage Analysis
The maximum NPL statistic obtained using all 11,244
polymorphic SNPs was 3.73 ( ) on chromo-Pp .0001
some 11p11. Under parametric analyses, an HLOD score
of 2.66 for the dominant model and an HLOD score of
4.03 for the recessive model (which corresponds to ge-
nomewide significance at the 5% level) were achieved at
the same chromosomal position. Chromosomes 5, 6, 10,
11, and 14 also attained NPL scores 12.0 and LOD scores
11.5, but these did not achieve the levels recommended
to indicate genomewide suggestive linkage (Lander and
Kruglyak 1995).
The presence of LD between markers has the potential
to inflate multipoint linkage statistics if the vectors of
inheritance have to be inferred on the basis of allele fre-
quencies (Evans and Cardon 2004; Huang et al. 2004).
This was of particular concern, because founders of many
of the pedigrees were not available to genotype and a
large proportion of the pedigrees were sib pairs. The
two most commonly used measures of LD are and′D
, and the properties of both statistics have been dis-2r
cussed extensively elsewhere (Hedrick 1987; Devlin and
Risch 1995). The behavior of these statistics is affected
by a number of factors, which can bias the accuracy of
LD estimation; in particular, is more robust to small′D
minor-allele frequencies, and is more robust to small2r
sample sizes. Thresholds of 0.4 and 0.7 for and ,2 ′r D
respectively, have been advocated to define high-LD SNPs
(John et al. 2004; Schaid et al. 2004). To identify high-
LD SNPs, we computed pairwise LD measured by ′D
and between consecutive SNPs. Figure 1 shows the2r
distributions of and according to the pairwise dis-2 ′r D
tance of SNPs within 2 Mb of each other, and figure 2
shows the distributions of and for all SNPs in our2 ′r D
data set. On the basis of the distributions of these sta-
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Figure 2 Distribution of pairwise and in the data set′ 2D r
tistics, we chose to use the statistic, with a threshold2r
of 0.4, to identify high-LD SNPs. The majority of high-
LD SNPs had values of ∼1.0 and were within 0.3 Mb2r
of each other (median distance 0.12 Mb; 25th–75th per-
centiles 0.02–0.32 Mb). Among the clusters of SNPs that
had , only one SNP (the centrally positioned2r 1 0.4
SNP) from each cluster was used in the linkage analyses.
With use of these criteria, a total of 1,968 SNPs were
excluded, which left a total of 9,276 SNPs.
NPL and LOD scores for analyses with and without
the high-LD SNPs are shown in figure 3. The panels
within figure 3 show that inclusion of high-LD SNPs in
the analysis can lead to inflated linkage statistics; how-
ever, in most cases, the overall profile of the linkage
statistics remains the same. The ICs for the analyses were
virtually identical, with a genomewide IC mean of 0.64
when high-LD SNPs were included, compared with a
genomewide IC mean of 0.63 when high-LD SNPs were
excluded. Plots of the IC for each chromosome showed
that exclusion of the high-LD SNPs had little impact on
overall chromosomal IC (data not shown). Therefore, it
seems reasonable to presume that any observable impact
on the linkage statistics after the removal of the high-
LD SNPs from our analyses is due to the effect of LD
between markers rather than to decreased IC.
The remaining 9,276 SNPs used in the linkage analy-
ses after removal of the high-LD SNPs had a calculated
median intermarker distance of 0.17 Mb (25th–75th per-
centile 0.06–0.38 Mb). Results of both parametric and
NPL analyses are summarized in table 2. Multipoint NPL
analysis of all 105 families resulted in a maximum NPL
score of 3.14, with a corresponding nominal one-sided
P value of .0008, at map position 11p11 (fig. 4 and table
2). This does not reach the empirical threshold for ge-
nomewide significance of 3.59, but it does attain the
suggestive linkage threshold of 2.80. At the same posi-
tion, an HLOD score of 1.85 (maximized with 41% of
families linked) was achieved under the assumption of
a dominant mode of inheritance, and an HLOD score
of 2.78 (maximized with 32% of families linked) was
achieved under the assumption of a recessive mode of
inheritance. These results are therefore evidence of sug-
gestive linkage at chromosome 11p11.
In addition, four other chromosomal positions (5q22-
23, 6p22, 10q25, and 14q32) displayed HLOD scores
11.15 (corresponding to a nominal P value !.01). How-
ever, none of these regions achieved the levels required
for genomewide suggestive evidence of linkage. Figure
4 shows multipoint HLOD scores generated using the
dominant and recessive models and for mul- log (P)10
tipoint NPL scores for all five chromosomes of interest.
Restriction of the analysis to the 89 pedigrees that con-
tained solely cases of B-cell CLL made no significant
difference to the linkage statistics. Specifically, the maxi-
mum NPL score obtained at chromosome 11p11 was
3.05 after LD removal.
Discussion
We have shown elsewhere that the use of high-density
SNP arrays provides an efficient method of conducting
genomewide linkage searches to identify Mendelian dis-
ease genes (Sellick et al. 2004b). Here, we have applied
the same technology to the mapping of a complex trait.
When evaluating the whole genome for linkage, a strin-
gent threshold is required. For a complex trait, LOD
Figure 3 NPL scores across each chromosome. In each plot, the dashed line shows NPL statistics obtained using all SNPs ( ),np 11,244
whereas the solid line shows NPL statistics obtained after exclusion of high-LD SNPs ( ).np 9,276
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Table 2
Results of Parametric and Nonparametric Analyses
CHROMOSOMAL
REGIONa
ANALYSIS RESULTS BY METHOD
Nonparametric Dominant Model Recessive Model
Maximum NPL P Maximum HLOD ab Maximum HLOD ab
5q22-23 2.01 .022 1.02 .29 1.35 .20
6p22 2.25 .012 1.05 .29 1.49 .22
10q25 2.12 .017 .94 .28 1.28 .22
11p11 3.14 .0008 1.85 .41 2.78 .32
14q32 2.03 .021 1.18 .34 .91 .19
a Location of maximum NPL scores 12.0 and maximum HLOD scores 11.15 (corresponding to a
nominal P value !.01) after the removal of high-LD SNP markers from analyses.
b The estimate of the proportion of families linked at a given genomic position.
scores 13.6 (equating to a genomewide significance level
of 5%) are generally accepted to provide significant evi-
dence of linkage, whereas LOD scores 12.2 are said to
provide suggestive evidence of linkage (Lander and Krug-
lyak 1995). Using a simulation approach, we established
corresponding empirical limits for the NPL statistic of
3.59 and 2.80 for significant and suggestive evidence of
linkage, respectively. In our genome scan, although we
did not identify any regions of significant linkage, we
found one region of suggestive linkage. Our results pro-
vide evidence of a major susceptibility locus on the per-
icentric region of chromosome 11 that influences the risk
of CLL—particularly in the more densely affected fam-
ilies—with characteristics consistent with an autosomal
recessive mode of inheritance. As expected, the multi-
point analyses that test for linkage in the presence of
heterogeneity (multipoint HLODs) gave the most power
to detect linkage in our sample set.
Apart from the evidence of suggestive linkage to chro-
mosome 11, we did not find any significant evidence of
linkage to any of the regions of the genome commonly
associated with cytogenetically detectable chromosomal
losses (6q, 13q14, or 17p) or gains (trisomy 12) in CLL.
There was, however, some support for linkage to chro-
mosome 14q32, a region of the genome that has been
shown to be involved in a small subset of B-cell CLL
cases (Karnolsky 2000; Gozzetti et al. 2004). It is pos-
sible that there is epistatic interaction between these
putative loci, but data from the analysis of additional
families are required to investigate this possibility.
To date, only one genomewide linkage search of fa-
milial CLL had been conducted (Goldin et al. 2003). That
study was based on 18 nuclear families containing 38
affected individuals, which inevitably had limited power
to detect linkage. The authors failed to find any genomic
regions that achieved statistical significance; however,
six regions—on chromosomes 1q, 3q, 6q, 12q, 13q, and
17p—were reported as supporting linkage with the stipu-
lation of a significance level of 0.02. None of these
regions coincide with our observations.
Our analyses concur with the findings of Schaid et al.
(2004) that the presence of LD between SNPs can lead
to inflated linkage statistics, as a consequence of the fact
that existing linkage software requires equilibrium be-
tween markers. The use of highly dense maps of SNPs
as markers is a relatively recent advance for linkage
analyses; as a result, there is as yet no consensus on the
methods to be used to manage the issue of LD between
SNPs. In our analysis, we excluded SNPs with high LD,
defined as those with pairwise LD measure . The2r 1 0.4
qualitative nature of our results was unaffected when
an alternative definition of high LD ( ) was used,′D 1 0.7
despite the differences in the distributions of the two
statistics. Although the approach implemented herein is
likely to address the most extreme impact of LD on the
linkage results, it is still possible that any remaining LD,
either pairwise values with or higher-order dis-2r ! 0.4
equilibria, influenced our results. Accepting these ca-
veats, we did find support for linkage of CLL to the
pericentric region of chromosome 11 in our genome-
wide scan. Previous studies by John et al. (2004) and
Schaid et al. (2004) investigated the impact of LD on
NPL and model-free (Kong and Cox) LOD scores, re-
spectively. They observed differing effects with removal
of LD: John et al. (2004) reported that a proportion of
SNPs in high LD slightly increased NPL scores, whereas
others slightly decreased NPL scores; Schaid et al. (2004)
reported that the presence of SNPs in high LD inflate
LOD scores. Our results show that high LD between
SNPs can inflate both NPL and parametric LOD scores.
We did not observe that the presence of high LD led to
decreased linkage statistics. Our results also agree with
those of Schaid et al. (2004) in that it is the existence
of LD between the SNP markers—and not the loss of
IC—that impacts the linkage statistics.
To date, no gene has been unambiguously implicated
in predisposition to B-cell CLL. A role for HLA alleles
has been documented for HL (Klitz et al. 1994), and
some association studies have also implicated variants
within or close to the major histocompatibility complex
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class II region in susceptibility to CLL (Machulla et al.
2001). The high frequency of somatic mutation in CLL,
coupled with a high prevalence of B-cell LPDs in ataxia
telangiectasia (AT [MIM 607585]) heterozygotes, sug-
gests carriers of ATM germline mutations have an in-
creased risk of B-cell tumors (Swift et al. 1987). Three
studies have previously assessed the contribution of
germline ATM mutations to CLL by screening the gene
in either familial or unselected cases (Bevan et al. 1999;
Stankovic et al. 1999; Yuille et al. 2002). Collectively,
the data provide some support, albeit at a nonsignificant
threshold, for the overrepresentation of ATM mutations
in CLL. However, on the basis of the linkage data pre-
sented herein, it is unlikely that germline mutations
within the ATM gene, which maps to chromosome
11q22.3, make a major contribution to the overall fa-
milial risk of CLL.
Although speculative at this juncture, there are several
interesting candidate genes involved in aspects of the
regulation of cellular proliferation and differentiation
(PTPRJ [protein tyrosine phosphatase, receptor type J]),
apoptosis (MADD [map kinase-activating death do-
main]) or the prevention of DNA damage (DDB2 [dam-
age-specific DNA binding protein 2]) in the linked re-
gion on chromosome 11, some of which have already
been shown to be differentially expressed in normal and
neoplastic cells.
It clearly would be highly advantageous to evaluate
a second series of families for linkage to the regions
detected in our analyses. As a consequence of limited
biospecimen availability, replication of the linkage find-
ings presented herein in an independent set of families
with CLL will be problematic. One strategy we are ac-
tively pursuing to increase the power of our existing
series of families is to screen unaffected family members
for monoclonal B-cell lymphocytosis. Subclinical levels
of monoclonal cells with an identical phenotype to indo-
lent CLL (termed “MCLUS” or “MBL”) have recently
been shown to be detectable in ∼3% of healthy indi-
viduals from the general population, by use of flow
cytometric analysis of CD5/CD20/CD79b expression on
CD19-gated B cells (Rawstron et al. 2002a). We have
also shown that MBL is significantly overrepresented in
relatives of patients with familial CLL (detectable in
∼14% of relatives) (Rawstron et al. 2002b), which sug-
gests that the phenotype is a surrogate marker of carrier
status. Screening unaffected family members from fami-
lies with CLL for MBL status therefore has the potential
for facilitating gene identification, through the increased
number of affected individuals within a given pedigree
who would be available for future linkage analyses.
Acknowledgments
The authors thank Drs. Aitchison, Antunovic, Auger, Bell,
Ben-Bassat, Berrebi, Bond, Capalbo, Chapman, Chipping,
Clark, Dearden, Douglas, Esteban, Gaminara, Garcia de Coca,
Garcia Diaz, Ginaldi, Jackson, Johnson, Knechtli, Lakhani,
Manoharan, Mehes, Mepham, Milne, Mineur, Morgenstern,
Nandi, Parker, Quabeck, Rassam, Reid, Ribeiro, Rist, Row-
lands, Stark, Stewart, Stockley, Sykes, Tham, Thompson, Tip-
lady, Treacy, Tringham, Van Den Neste, Westerman, and Wick-
ham, for their contribution of families with CLL; and the
patients, for their participation in this study. G.S.S. was a re-
cipient of a postdoctoral research fellowship from Leukemia
Research, and E.L.W., a postdoctoral research fellowship from
Cancer Research United Kingdom. A proportion of the geno-
typing was undertaken by Jo McBride at MRC Geneservices,
U.K. The work was supported by grants from Leukemia Re-
search and the Arbib Foundation (to R.S.H. and D.C.) and
from Novo Nordic (to V.J.).
Web Resources
The URLs for data presented herein are as follows:
Affymetrix NetAffx, http://www.affymetrix.com/analysis/index
.affx
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for CLL, NHL, HL, and AT)
SNPLINK, http://www.icr.ac.uk/cancgen/molgen/MolPopGen
_Bioinformatics.htm
University of California–Santa Cruz Human Genome Browser,
http://genome.ucsc.edu/cgi-bin/hgGateway
References
Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002)
Merlin—rapid analysis of dense genetic maps using sparse
gene flow trees. Nat Genet 30:97–101
Bevan S, Catovsky D, Marossy A, Matutes A, Popat S, An-
tonovic P, Bell A, Berrebi A, Gaminara E, Quabeck K, Ri-
beiro I, Mauro FR, Stark P, Sykes H, van Dongen J, Wim-
peris J, Wright S, Yuille MR, Houlston RS (1999) Linkage
analysis for ATM in familial B cell chronic lymphocytic leu-
kaemia. Leukemia 13:1497–1500
Cartwright RA, Bernard SM, Bird CC, Darwin CM, O’Brien
C, Richards ID, Roberts B, McKinney PA (1987) Chronic
lymphocytic leukaemia: case-control epidemiological study in
Yorkshire. Brit J Cancer 56:79–82
Devlin B, Risch N (1995) A comparison of linkage disequilib-
rium measure for fine-scale mapping. Genomics 29:311–322
Evans DM, Cardon LR (2004) Guidelines for genotyping in
genomewide linkage studies: single-nucleotide–polymorphism
maps versus microsatellite maps. Am J Hum Genet 75:687–
692
Faraway JJ (1993) Distribution of the admixture test for the
detection of linkage under heterogeneity. Genet Epidemiol 10:
75–83
Goldin LR, Ishibe N, Sgambati M, Marti GE, Fontaine L, Lee
MP, Kelley JM, Scherpbier T, Buetow KH, Caporaso NE
(2003) A genome scan of 18 families with chronic lympho-
cytic leukaemia. Br J Haematol 121:866–873
Goldin LR, Pfeiffer RM, Li X, Hemminki K (2004) Familial
risk of lymphoproliferative tumors in families of patients
with chronic lymphocytic leukemia: results from the Swedish
family-cancer database. Blood 104:1850–1854
Sellick et al.: Genomewide Linkage Search of Familial CLL 429
Gozzetti A, Crupi R, Tozzuoli D, Raspadori D, Forconi F, Lauria
F (2004) Molecular cytogenetic analysis of B-CLL patients
with aggressive disease. Hematology 9:383–385
Gudbjartsson DF, Jonasson K, Frigge ML, Kong A (2000) Al-
legro, a new computer program for multipoint linkage analy-
sis. Nat Genet 25:12–13
Gunz FW, Gunz JP, Veale AM, Chapman CJ, Houston IB (1975)
Familial leukaemia: a study of 909 families. Scand J Haema-
tol 15:117–131
Hedrick PW (1987) Gametic disequilibrium measures: proceed
with caution. Genetics 117:331–341
Houlston RS, Sellick G, Yuille M, Matutes E, Catovsky D (2003)
Causation of chronic lymphocytic leukemia—insights from
familial disease. Leuk Res 27:871–876
Huang Q, Shete S, Amos CI (2004) Ignoring linkage disequi-
librium among tightly linked markers induces false-positive
evidence of linkage for affected sib pair analysis. Am J Hum
Genet 75:1106–1112
John S, Shephard N, Liu G, Zeggini E, Cao M, Chen W, Vasavda
N, Mills T, Barton A, Hinks A, Eyre S, Jones KW, Ollier W,
Silman A, Gibson N, Worthington J, Kennedy GC (2004)
Whole-genome scan, in a complex disease, using 11,245 sin-
gle-nucleotide polymorphisms: comparison with microsatel-
lites. Am J Hum Genet 75:54–64
Karnolsky IN (2000) Cytogenetic abnormalities in chronic lym-
phocytic leukemia. Folia Med (Plovdiv) 42:5–10
Klitz W, Aldrich CL, Fildes N, Horning SH, Begovich AB (1994)
Localization of predisposition to Hodgkin disease in the HLA
class II region. Am J Hum Genet 54:497–505
Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Para-
metric and nonparametric linkage analysis: a unified multi-
point approach. Am J Hum Genet 58:1347–1363
Lander E, Kruglyak L (1995) Genetic dissection of complex
traits: guidelines for interpreting and reporting linkage re-
sults. Nat Genet 11:241–247
Linet MS, Van Natta ML, Brookmeyer R, Khoury MJ, Mc-
Caffrey LD, Humphrey RL, Szklo M (1989) Familial cancer
history and chronic lymphocytic leukaemia: a case-control
study. Am J Epidemiol 130:655–664
Machulla HK, Muller LP, Schaaf A, Kujat G, Schonermarck
U, Langner J (2001) Association of chronic lymphocytic leu-
kaemia with specific alleles of the HLA-DR4:DR53:DQ8
haplotype in German patients. Int J Cancer 92:203–207
Matsuzaki H, Loi H, Dong S, Tsai YY, Fang J, Law J, Di X,
Liu WM, Yang G, Liu G, Huang J, Kennedy GC, Ryder TB,
Marcus GA, Walsh PS, Shriver MD, Puck JM, Jones KW, Mei
R (2004) Parallel genotyping of over 10,000 SNPs using a
one-primer assay on a high-density oligonucleotide array.
Genome Res 14:414–425
Mu¨ller-Hermelink HK, Montserrat E, Catovsky D, Harris NL
(2001) Chronic lymphocytic leukaemia/small lymphocytic
lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW
(eds) World Health Organization classification of tumours:
pathology and genetics of tumours of haematopoietic and
lymphoid tissues. IARC Press, Lyon, pp 127–130
Pottern LM, Linet M, Blair A, Dick F, Burmeister LF, Gibson
R, Schuman LM, Fraumeni JF Jr (1991) Familial cancers
associated with subtypes of leukaemia and non-Hodgkin’s
lymphoma. Leuk Res 15:305–314
Radovanovic Z, Markovic-Denic L, Jakovic S (1994) Cancer
mortality of family members of patients with chronic lym-
phocytic leukaemia. Eur J Epidemiol 10:211–213
Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA,
Evans PA, O’Connor SJ, Richards SJ, Morgan GJ, Jack AS,
Hillmen P (2002a) Monoclonal B lymphocytes with the char-
acteristics of “indolent” chronic lymphocytic leukemia are
present in 3.5% of adults with normal blood counts. Blood
100:635–639
Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B,
Richards SJ, Jack AS, Matutes E, Catovsky D, Hillmen P,
Houlston RS (2002b) Inherited predisposition to CLL is de-
tectable as subclinical monoclonal B-lymphocyte expansion.
Blood 100:2289–2290
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg
L, Mariotto A, Fay MP, Feuer EJ, Edwards BK (eds) (2003)
SEER Cancer Statistics Review 1975–2000. National Cancer
Institute, Bethesda. http://seer.cancer.gov/csr/1975_2000/ (ac-
cessed July 25, 2005)
Schaid DJ, Guenther JC, Christensen GB, Hebbring S, Rosenow
C, Hilker CA, McDonnell SK, Cunningham JM, Slager SL,
Blute ML, Thibodeau SN (2004) Comparison of microsa-
tellites versus single-nucleotide polymorphisms in a genome
linkage screen for prostate cancer–susceptibility loci. Am J
Hum Genet 75:948–965
Schweitzer M, Melies M, Ploen JE (1973) Chronic lymphocytic
leukaemia in 5 siblings. Scand J Haemat 11:97–105
Sellick G, Catovsky D, Houlston RS (2004a) Familial chronic
lymphocytic leukaemia. In: Hamblin T, Johnson S, Miles A
(eds) The effective management of chronic lymphocytic leu-
kaemia. Aesculapius Medical Press, London, pp 3–15
Sellick GS, Longman C, Tolmie J, Newbury-Ecob R, Geenhalgh
L, Hughes S, Whiteford M, Garrett C, Houlston RS (2004b)
Genomewide linkage searches for Mendelian disease loci can
be efficiently conducted using high-density SNP genotyping
arrays. Nucleic Acids Res 32:e164
Stankovic T, Weber P, Stewart G, Bedenham T, Byrd OJ, Mur-
ray J, Moss PAH, Taylor AMR (1999) Inactivation of ataxia
telangectasia mutated gene in B-cell chronic lymphocytic leu-
kaemia. Lancet 353:26–29
Swift M, Reitnauer PJ, Morrell D, Chase CL (1987) Breast and
other cancers in families with ataxia-telangiectasia. N Engl
J Med 316:1289–1294
Webb EL, Sellick GS, Houlston RS (2005) SNPLINK: multi-
point linkage analysis of densely distributed SNP data incor-
porating automated linkage disequilibrium removal. Bioin-
formatics 21:3060–3061
Whittemore AS, Halpern J (1994) A class of tests for linkage
using affected pedigree members. Biometrics 50:118–127
Yuille MR, Condie A, Hudson CD, Bradshaw PS, Stone EM,
Matutes E, Catovsky D, Houlston RS (2002) ATM mutations
are rare in familial chronic lympohcytic leukaemia. Blood 100:
603–609
